SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
Dwivedi, P; Chutipongtanate, S; Muench, DE; Azam, M; Grimes, HL; Greis, KD.
Proteomics: Clinical Applications.
2020;
14:e1900144-1900144.
Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors.
Dwivedi, P; Muench, DE; Wagner, M; Azam, M; Grimes, HL; Greis, KD.
Scientific Data.
2019;
6.
Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK.
Ramkissoon, A; Chaney, KE; Milewski, D; Williams, KB; Williams, RL; Choi, K; Miller, A; Kalin, TV; Pressey, JG; Szabo, S; et al.
Clinical Cancer Research.
2019;
25:clincanres.3224.2018-clincanres.3224.2018.
The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes.
Lin, P; Ren, Y; Yan, X; Luo, Y; Zhang, H; Kesarwani, M; Bu, J; Zhan, D; Zhou, Y; Tang, Y; et al.
Haematologica: the hematology journal.
2019;
104:485-496.
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence.
Kesarwani, M; Kincaid, Z; Azam, M.
Jove-Journal of Visualized Experiments.
2019;
2019.
Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.
Dwivedi, P; Muench, DE; Wagner, M; Azam, M; Grimes, HL; Greis, KD.
Leukemia.
2019;
33:75-87.
Expansion of EPOR-negative macrophages besides erythroblasts by elevated EPOR signaling in erythrocytosis mouse models.
Wang, J; Hayashi, Y; Yokota, A; Xu, Z; Zhang, Y; Huang, R; Yan, X; Liu, H; Ma, L; Azam, M; et al.
Haematologica: the hematology journal.
2018;
103:69-79.
MEK/ERK addiction in CNL/aCML.
Kesarwani, M; Kincaid, Z; Azam, M.
Oncotarget.
2017;
8:99215-99216.
Enhanced MAPK signaling is essential for CSF3R-induced leukemia.
Rohrabaugh, S; Kesarwani, M; Kincaid, Z; Huber, E; Leddonne, J; Siddiqui, Z; Khalifa, Y; Komurov, K; Grimes, HL; Azam, M.
Leukemia.
2017;
31:1770-1778.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Kesarwani, M; Kincaid, Z; Gomaa, A; Huber, E; Rohrabaugh, S; Siddiqui, Z; Bouso, MF; Latif, T; Xu, M; Komurov, K; et al.
Nature Medicine.
2017;
23:472-482.